Interim FDG PET/CT to predict progression-free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL).
Ashley Knight-Greenfield
No relevant relationships to disclose
Richard Aaron Marshall
No relevant relationships to disclose
Martin Hutchings
No relevant relationships to disclose
John Doucette
No relevant relationships to disclose
Jamie Stern
No relevant relationships to disclose
Morton Coleman
No relevant relationships to disclose
Lale Kostakoglu
No relevant relationships to disclose